Comparison of azlocillin and ticarcillin in the treatment of urinary tract infection.
This prospective, controlled, randomized double blind study compared the safety and effectiveness of intravenous azlocillin at a dosage of 6 g/day in three divided doses with that of intravenous ticarcillin at 8 g/day in four divided doses for the treatment of urinary tract infections in 35 patients. The clinical and bacteriological responses among the 26 courses evaluable for drug effectiveness (13 in each group) appeared to be somewhat more favourable in the azlocillin treatment group (92.3%) than the ticarcillin group (69.2%). However, statistically, both treatment groups did not differ in a significant manner in regard to effectiveness or adverse reactions. Of the patients who were followed for relapses for three-four weeks after treatment, 66.7% of the azlocillin group and 45.5% of the ticarcillin group remained free of the original infecting organism. Local and systemic tolerance for both drugs was excellent.
D000368:Aged; D001390:Azlocillin; D006801:Humans; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011897:Random Allocation; D012008:Recurrence; D013982:Ticarcillin / Q000009:adverse effects / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D010406:Penicillins; D013982:Ticarcillin; D001390:Azlocillin